0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Biperiden (Akineton) in Parkinsonism

WILLIAM H. TIMBERLAKE, M.D.; ROBERT S. SCHWAB, M.D.; ALBERT C. ENGLAND JR., M.D.
Arch Neurol. 1961;5(5):560-564. doi:10.1001/archneur.1961.00450170098012.
Text Size: A A A
Published online

The pharmacologic treatment of Parkinsonism is severely limited in effectiveness since at best only 20% to 30% reduction of symptoms can be achieved. Accordingly, the search continues for new medicines or modifications of present medicines which will give better control of symptoms with fewer side-effects. Biperiden (Akineton), 2-piperidino-1-phenyl-1-bicycloheptemyl-propanol, is such an analogue of trihexyphenidyl (Artane), whose structural relationships are shown in the figure.

Haas and Klavehn1 in animal experiments found that biperiden has 4 times the antinicotinic action of atropine, caramiphen (Panparnit), or trihexyphenidyl. Such antinicotinic action in animals has characterized synthetic drugs which proved to be effective against Parkinsonism. Biperiden's peripheral visceral anticholinergic action was greater than that of trihexyphenidyl, equal to that of papaverine and less than that of atropine. Its midriatic, antisialagogic, and constipative effects equalled those of trihexyphenidyl.

Clinical trials of biperiden in Parkinsonism at European clinics2-8 has suggested considerable improvement in rigidity, tremor,

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();